Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vasopressin V2 Receptor Antagonist · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Vasopressin V2 Receptor Antagonist | DRUG | - |
* Men or women with chronic heart failure (NYHA Class IIIB and IV). * Women must be post-menopausal or surgically sterilized; they cannot be pregnant or nursing. * Age 21 to 80 years. * Chronic heart failure of at least 3 months duration. For 2 months prior to screening, patients must have had sympt...
Vasopressin V2 Receptor Antagonist is being developed by Sanofi for chronic heart failure, a cardiovascular condition. It is a small molecule therapeutic that has been studied in patients with severe chronic heart failure. The drug remains investigational and has not been approved for any indication.
Vasopressin V2 Receptor Antagonist targets the AVPR2, AVPR1A, and AVPR1B receptors. These are vasopressin receptors, and the compound acts as an agonist at these targets. By binding to these receptors, it modulates vasopressin signaling, which is relevant in chronic heart failure.
Sanofi, which trades under the ticker SNY, is the developer of Vasopressin V2 Receptor Antagonist. The company is responsible for the clinical development of this small molecule agent for chronic heart failure.
Vasopressin V2 Receptor Antagonist is in Phase 2 clinical development. It has completed one Phase 2 trial and is not currently listed as active in any ongoing trials. The drug is investigational and has not received FDA approval.
Vasopressin V2 Receptor Antagonist has been evaluated in one completed Phase 2 trial, NCT00032747, titled AQUAVIT. This randomized, double-blind study enrolled 338 patients with severe chronic heart failure across the United States, Canada, and the United Kingdom. The trial included adults 18 years and older of all sexes.